Rigel Pharmaceuticals, Inc.
RIGL
Rank in Stocks
#9811
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides... Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Share Price
$42.05
Last synced: 2026-11-09
Market Cap
$785.49M
Change (1 day)
6.05%
Change (1 year)
10.80%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Rigel Pharmaceuticals, Inc. (RIGL)
Category
Healthcare
Operating Margin for Rigel Pharmaceuticals, Inc. (RIGL)
Operating Margin as of November 2026 TTM: 31.45%
According to Rigel Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 31.45%. At the end of 2025 the company had an operating margin of 42.63%.
Operating Margin history for Rigel Pharmaceuticals, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 31.45% | -26.23% |
| 2025 | 42.63% | 216.01% |
| 2024 | 13.49% | -176.95% |
| 2023 | -17.53% | -62.06% |
| 2022 | -46.20% | 451.97% |
| 2021 | -8.37% | -68.62% |
| 2020 | -26.67% | -77.11% |
| 2019 | -116.53% | -28.64% |
| 2018 | -163.30% | -90.80% |
| 2017 | -1,775.56% | 418.94% |
| 2016 | -342.15% | 91.07% |
| 2015 | -179.07% | -83.81% |
| 2014 | -1,106.05% | -11.61% |
| 2013 | -1,251.31% | -71.67% |
| 2012 | -4,416.76% | 142.91% |
| 2011 | -1,818.27% | -6,536.35% |
| 2010 | 28.25% | -100.19% |
| 2009 | -14,938.27% | 0.00% |
| 2008 | 0.00% | -100.00% |
| 2007 | -631.17% | 390.80% |
| 2006 | -128.60% | -55.65% |
| 2005 | -289.98% | -75.87% |
| 2004 | -1,201.50% | 225.34% |
| 2003 | -369.31% | 57.52% |
| 2002 | -234.46% | 43.74% |
| 2001 | -163.11% | -15.47% |
| 2000 | -192.96% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -98.77% |
US
|
|
| -149.01% | -104.74% |
US
|
|
| 25.57% | -99.19% |
AU
|
|
| 31.23% | -99.01% |
BE
|
|
| 29.35% | -99.07% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Rigel Pharmaceuticals, Inc.'s operating margin
What is Rigel Pharmaceuticals, Inc.'s operating margin?
Rigel Pharmaceuticals, Inc.'s operating margin is 31.45%, as of Nov 2026.
What was Rigel Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Rigel Pharmaceuticals, Inc.'s operating margin was 42.63%, compared with 13.49% in 2024.
How has Rigel Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Rigel Pharmaceuticals, Inc.'s operating margin was highest in 2025 (42.63%) and lowest in 2022 (-46.20%).
How does Rigel Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Rigel Pharmaceuticals, Inc.'s operating margin (31.45%) is higher than that of 4 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.